An interventional study of Semaglutide in Food Addiction Tendency, Obesity and Overweight, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Basic science
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.
Among the 145 studies testing semaglutide in Obesity, this one is the 125th largest by planned enrollment, is one of 30 that started in 2026, is one of 18 with no phase, reaches primary completion later than 50 of the 78 other live ones, and was the 125th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 25 · Phase 3 47 · Phase 4 40
First in 2014; this study’s year is marked. 30 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 100 across the 145 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 145 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
17 studies in Obesity by Seoul National University Hospital: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 17 studies in Obesity by Seoul National University Hospital, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 with no phase, and was the 17th registered.
Seoul National University Hospital’s Obesity studies by the year they started, since 2009.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 145 studies testing semaglutide in Obesity, from their registry updates:
Among Seoul National University Hospital’s 17 in Obesity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate how semaglutide affects the way the brain responds to food in adults with obesity and food addiction tendencies.
The main goals of this study are:
Adults with obesity and food addiction tendencies will join this study. Each participant will receive semaglutide treatment for 8 weeks. Each participant will have two brain scans using [11C]raclopride PET.
During each PET scan, participants will:
Background and Rationale
GLP-1 receptor agonists, including semaglutide, are effective treatments for obesity. However, the brain mechanisms underlying their effects on appetite, food reward, and eating behavior remain incompletely understood. Food-related visual and olfactory cues may engage dopamine-mediated reward pathways during the pre-ingestive phase, and post-ingestive signals may further influence dopamine signaling after food intake.
This study will use [11C]raclopride positron emission tomography (PET) to assess dopamine-related binding measures in the human brain. The study will examine whether semaglutide changes dopamine-related brain responses during food cue and drink exposure and during the post-ingestive period.
This is a prospective clinical trial using a 2-by-2 crossover design. Participants will receive once-weekly semaglutide treatment for 8 weeks and will undergo two [11C]raclopride PET scans. The scans will be performed under conditions with and without the effect of semaglutide, depending on group assignment.
Before each PET imaging session, participants will complete baseline assessments, including body measurements, psychological surveys, and computer-based cognitive tasks. [11C]raclopride will then be administered according to the PET protocol. Participants will undergo brain PET imaging while lying in the scanner.
During the imaging session, participants will complete a standardized chocolate milk drink task. This task includes a baseline period, exposure to chocolate milk images, smelling the chocolate milk drink, and the post-ingestive stage using the chocolate milk drink delivered through a tube. During the scan, participants will use a tablet to rate hunger, desire for the chocolate milk drink, and liking of the drink at set time points.
The same PET task procedures will be used across study conditions. This will allow researchers to compare dopamine-related PET measures, psychological survey results, and cognitive task results between conditions with and without the effect of semaglutide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo a baseline \[11C\]raclopride PET scan before semaglutide treatment. They then receive an 8-week semaglutide dose-escalation treatment, followed by a second \[¹¹C\]raclopride PET scan at the end of treatment.
Drug: Semaglutide
Participants first receive an 8-week semaglutide dose-escalation treatment and undergo a \[¹¹C\]raclopride PET scan at the end of treatment. After an 8-week washout period, they undergo a second \[¹¹C\]raclopride PET scan.
Drug: Semaglutide
Participants receive an 8-week subcutaneous semaglutide dose-escalation treatment using Wegovy: 0.25 mg once weekly for the first 4 weeks, followed by 0.5 mg once weekly for the next 4 weeks.
Also known as: Wegovy
Change in Dopamine Binding Potential During the Look, Smell, and Drink Period
Dopamine D2/D3 receptor binding potential is measured using \[11C\]raclopride PET during the food cue and drink period. The outcome is the within-participant difference in binding potential between the on-drug and off-drug/post-washout conditions.
Time frame: Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
Change in Dopamine Binding Potential During the Post-Ingestive Period
Dopamine D2/D3 receptor binding potential is measured using \[11C\]raclopride PET during the post-ingestive period after the drink. The outcome is the within-participant difference in binding potential between the on-drug and off-drug/post-washout conditions.
Time frame: Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
State Food Craving Score
State food craving is assessed using the General Food Cravings Questionnaire-State (G-FCQ-S). Each of the 15 items is evaluated on a 0 to 100 scale, where higher scores indicate greater intensity of the felt state.
Time frame: Immediately before and after PET imaging. Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
Chocolate Milk Liking, Chocolate Milk Wanting, and Fullness Ratings (VAS-100)
Liking and wanting for the chocolate milk stimulus, as well as general fullness, are assessed repeatedly during PET imaging using 0-to-100 visual analogue scale ratings. For liking and wanting, higher scores indicate greater liking of or desire for the chocolate milk stimulus. For fullness, higher scores indicate greater subjective fullness. Ratings are collected at 15 predefined time points during each PET scan.
Time frame: During each 92-minute PET scan, at 10, 20, 30, 40, 50, 51, 54, 57, 60, 65, 70, 75, 80, 85, and 90 minutes.
Food-Specific Attentional Bias
Food-specific attentional bias is assessed using a computer-based dot-probe task with webcam-based eye tracking. Bias is calculated from reaction time differences between probes replacing food versus neutral images, and from gaze-based measures including dwell time toward food versus neutral images and first saccade direction. Higher values indicate greater attentional bias toward food stimuli.
Time frame: Before PET imaging. Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
Plan to share: No — IPD will not be shared publicly because the current protocol does not include a plan for public sharing of individual participant data. Participant data will be managed in accordance with the approved protocol and institutional privacy protection requirements.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Feb 2028, 19 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 19 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Seoul National University Hospital →